Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the biphenyl carboxylic acids class. It is primarily used as a research tool and chemical intermediate. The compound acts as an inhibitor of Bcl‑2-like protein 1 (Bcl-xL), a member of the Bcl‑2 family involved in regulating apoptosis. By binding to Bcl‑2-like protein 1 with moderate affinity (KD ~400 μM), it has been explored for its potential in developing selective anti-cancer agents targeting apoptotic pathways[1][8]. There are no approved medical indications or clinical trials for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4'-fluoro-1,1'-biphenyl-4-carboxylic acid.